| Literature DB >> 31916028 |
A A Withagen-Koster1, R C van Kleef2, F Eijkenaar2.
Abstract
Most health insurance markets with premium-rate restrictions include a risk equalization system to compensate insurers for predictable variation in spending. Recent research has shown, however, that even the most sophisticated risk equalization systems tend to undercompensate (overcompensate) groups of people with poor (good) self-reported health, confronting insurers with incentives for risk selection. Self-reported health measures are generally considered infeasible for use as an explicit 'risk adjuster' in risk equalization models. This study examines an alternative way to exploit this information, namely through 'constrained regression' (CR). To do so, we use administrative data (N = 17 m) and health survey information (N = 380 k) from the Netherlands. We estimate five CR models and compare these models with the actual Dutch risk equalization model of 2016 which was estimated by ordinary least squares (OLS). In the CR models, the estimated coefficients are restricted, such that the under-/overcompensation for groups based on self-reported general health is reduced by 20, 40, 60, 80, or 100%. Our results show that CR can improve outcomes for groups that are not explicitly flagged by risk adjuster variables, but worsens outcomes for groups that are explicitly flagged by risk adjuster variables. Using a new standardized metric that summarizes under-/overcompensation for both types of groups, we find that the lighter constraints can lead to better outcomes than OLS.Entities:
Keywords: Constrained regression; Health insurance; Risk equalization; Risk selection; Survey data
Mesh:
Year: 2020 PMID: 31916028 PMCID: PMC7214515 DOI: 10.1007/s10198-019-01146-y
Source DB: PubMed Journal: Eur J Health Econ ISSN: 1618-7598
Fig. 1Frequencies per morbidity-based risk adjuster for the (un)balanced sample and total Dutch adult population. The horizontal axis shows groups of individuals flagged by a morbidity-based risk adjuster included in the Dutch risk equalization model 2016. The abbreviations refer to pharmacy-based cost groups (PCGs), diagnosis-based cost groups (DCGs), multiple-year high cost groups (MHCGs), and durable medical equipment cost groups (DMECG)
Fig. 2Average spending per morbidity-based risk adjuster for the (un)balanced sample and total Dutch adult population. The horizontal axis shows groups of individuals flagged by a morbidity-based risk adjuster included in the Dutch risk equalization model 2016. The abbreviations refer to pharmacy-based cost groups (PCGs), diagnosis-based cost groups (DCGs), multiple-year high cost groups (MHCGs), and durable medical equipment cost groups (DMECG)
Description and outcomes of the six models
| Model | CPM (%) | |
|---|---|---|
| OLS (0%) | 27.9 | 29.9 |
| CR-20%: constrained regression model with 20% reduction of under-/overcompensations for the two groups based on self-reported general health | 27.9 | 30.0 |
| CR-40%: constrained regression model with 40% reduction of under-/overcompensations for the two groups based on self-reported general health | 27.8 | 30.0 |
| CR-60%: constrained regression model with 60% reduction of under-/overcompensations for the two groups based on self-reported general health | 27.8 | 29.9 |
| CR-80%: constrained regression model with 80% reduction of under-/overcompensations for the two groups based on self-reported general health | 27.7 | 29.7 |
| CR-100%: constrained regression model with 100% reduction of under-/overcompensations for the two groups based on self-reported general health | 27.6 | 29.3 |
Mean under-/overcompensation by six models in euros per person per year for groups identified in the health survey
| Survey group | Size of group (%) | Mean spending in euros (2013) | Mean under-/overcompensation per person per year in euros (2013) | |||||
|---|---|---|---|---|---|---|---|---|
| OLS (0%) | CR-20% | CR-40% | CR-60% | CR-80% | CR-100% | |||
| Self-reported general health | ||||||||
| Fair, poor or very poor | 27.6 | 5602 | − 494* | − 396* | − 297* | − 198* | − 100* | − 1 |
| Good or very good | 72.4 | 1439 | 156* | 125* | 93* | 62* | 31* | − 1 |
| Self-reported chronic condition (past 12 months) | ||||||||
| At least one | 60.1 | 3376 | − 122* | − 92* | − 62* | − 32* | − 2 | 28* |
| None | 28.2 | 1010 | 178* | 130* | 83* | 35* | − 13* | − 60* |
| 1 | 25.6 | 2182 | 50* | 41* | 31* | 22* | 13 | 4 |
| 2 | 15.1 | 3095 | − 126* | − 105* | − 83* | − 61* | − 39* | − 17 |
| 3 | 8.4 | 4352 | − 348* | − 289* | − 229* | − 169* | − 109* | − 49* |
| 4 | 11.0 | 6443 | − 427* | − 297* | − 166* | − 36* | 95* | 226* |
| Missing | 11.7 | 2396 | 26* | 29* | 33* | 37* | 41* | 45* |
| Diabetes (ever) | ||||||||
| Yes | 8.2 | 6739 | − 192* | − 46* | 99* | 246* | 392* | 538* |
| No | 86.9 | 2116 | 16 | 4 | − 7 | − 18 | − 28* | − 39* |
| Missing | 5.0 | 3077 | − 47* | − 27* | − 6 | 14 | 34* | 55* |
| Stroke (ever) | ||||||||
| Yes | 4.2 | 7626 | − 811* | − 686* | − 561* | − 435* | − 310* | − 184* |
| No | 91.6 | 2251 | 28* | 23* | 18 | 14 | 9 | 4 |
| Missing | 4.2 | 2903 | − 57* | − 42* | − 27* | − 12 | 3 | 18 |
| Heart attack (ever) | ||||||||
| Yes | 5.0 | 7631 | − 456* | − 320* | − 184* | − 47* | 89* | 225* |
| No | 90.9 | 2241 | 19 | 13 | 8 | 3 | − 3 | − 8 |
| Missing | 4.1 | 2955 | − 76* | − 61* | − 45* | − 29* | − 14 | 2 |
| Cancer (ever) | ||||||||
| Yes | 9.9 | 6517 | − 433* | − 351* | − 270* | − 188* | − 106* | − 24 |
| No | 86.3 | 2122 | 34* | 26* | 20* | 13 | 6 | − 1 |
| Missing | 3.8 | 2739 | − 33* | − 21 | − 10 | 2 | 14 | 26* |
OLS ordinary least squares, CR constrained regression
*Statistically significantly different from zero (P < 0.05)
Mean under-/overcompensation by six models in euros per person per year for groups (not) flagged by the morbidity-based risk adjusters of the risk equalization model 2016
| Group | Size of group (%) | Mean spending in euros (2013) | Mean under-/overcompensation per person per year in euros (2013) | |||||
|---|---|---|---|---|---|---|---|---|
| OLS (0%) | CR-20% | CR-40% | CR-60% | CR-80% | CR-100% | |||
| Morbidity | ||||||||
| Yes | 25.0 | 5584 | 2 | 111* | 220* | 330* | 439* | 548* |
| No | 75.0 | 978 | − 1 | − 37* | − 74* | − 110* | − 147* | − 183* |
| PCG | ||||||||
| Yes | 19.3 | 5669 | 15* | 134* | 255* | 375* | 496* | 616* |
| No | 80.7 | 1286 | − 3* | − 32* | − 61* | − 90* | − 118* | − 147* |
| DCG | ||||||||
| Yes | 9.3 | 8179 | 0 | 145* | 291* | 437* | 583* | 729* |
| No | 90.7 | 1514 | 0 | − 15* | − 30* | − 45* | − 59* | − 74* |
| MYHCG | ||||||||
| Yes | 5.8 | 12,137 | 0 | 211* | 423* | 634* | 846* | 1057* |
| No | 94.2 | 1524 | 0 | − 13* | − 26* | − 38* | − 51* | − 64* |
| DMECG | ||||||||
| Yes | 0.9 | 14,727 | 0 | 167* | 335* | 502* | 670* | 838* |
| No | 99.1 | 2020 | 0 | − 1 | − 3 | − 4* | − 6* | − 7* |
| Physiotherapy | ||||||||
| Yes | 2.0 | 8769 | 0 | 156* | 313* | 470* | 627* | 784* |
| No | 98.0 | 1998 | 0 | − 3* | − 6* | − 9* | − 13* | − 16* |
| Home care | ||||||||
| Yes | 2.2 | 16,658 | 0 | 231* | 463* | 695* | 927* | 1158* |
| No | 97.8 | 1827 | 0 | − 5* | − 10* | − 15* | − 19* | − 24* |
| Geriatric rehabilitation care | ||||||||
| Yes | 0.2 | 13,372 | 0 | 210* | 422* | 633* | 844* | 1055* |
| No | 99.8 | 2109 | 0 | 0 | − 1 | − 1 | − 2 | − 2 |
Morbidity is defined as being classified in one of the seven morbidity-based risk adjusters of the risk equalization model. No morbidity is defined as being classified in none of the seven morbidity-based risk adjusters of the risk equalization model 2016
OLS ordinary least squares, CR constrained regression, PCGs pharmacy-based cost groups, DCGs diagnosis-based cost groups, MHCGs multiple-year high cost groups, DMECG durable medical equipment cost groups
*Statistically significantly different from zero (P < 0.05)
Fig. 3Mean under-/overcompensations under six models in euros per person per year for groups based on a cross tabulation of self-reported general health by yes/no morbidity. The abbreviations stand for ordinary least squares (OLS) and constrained regression (CR). Morbidity is defined as being classified in one of the seven morbidity-based risk adjusters of the risk equalization model. No morbidity is defined as being classified in none of the seven morbidity-based risk adjusters of the risk equalization model
Fig. 4Outcomes of six models for metric S for groups based on a cross tabulation of self-reported general health and yes/no morbidity. The abbreviations stand for ordinary least squares (OLS) and constrained regression (CR). Metric S is calculated using Eq. (1). The constraint is a % reduction in under- and overcompensation on the group with a (very) good general health and the group with a fair or (very) poor general health
Fig. 5Outcomes of six models for metric S with equal weighting and differentiated weighting of subgroups. The outcomes with equal weighting of subgroups are calculated using Eq. (1). Differentiated weighting means that the result for each of the four groups is weighted with the average spending of that group and that an undercompensation is weighted twice as heavy as an overcompensation. The horizontal axis represents the different models. The series ’equal weighting’ is equivalent to the outcomes of Fig. 4
Under-/overcompensations in euros for survey groups of specific self-reported conditions in the last 12 months estimated with ordinary least squares (OLS) and constrained regression (CR)
| Groups | Size (%) | Mean spending in euros | Mean under-/overcompensation per person per year in euros (2013) | |||||
|---|---|---|---|---|---|---|---|---|
| OLS (0%) | CR-20% | CR-40% | CR-60% | CR-80% | CR-100% | |||
| Stroke | ||||||||
| Yes | 0.7 | 9117 | − 722* | − 561* | − 399* | − 237* | − 75* | 87* |
| No | 95.3 | 2368 | 9 | 7 | 5 | 3 | 1 | − 1 |
| Missing | 4.0 | 3074 | − 92* | − 74* | − 57* | − 39* | − 21 | − 4 |
| Heart attack | ||||||||
| Yes | 0.5 | 8509 | − 503* | − 333* | − 162* | 9 | 180* | 351* |
| No | 95.3 | 2376 | 7 | 4 | 3 | 1 | − 1 | − 3 |
| Missing | 4.2 | 3102 | − 82* | − 62* | − 43* | − 23* | − 4 | 16 |
| Heart condition | ||||||||
| Yes | 3.2 | 8918 | − 790* | − 630* | − 469* | − 309* | − 148* | 12 |
| No | 92.6 | 2267 | 18 | 13 | 8 | 4 | − 1 | − 6 |
| Missing | 4.2 | 2908 | − 7 | 10 | 27* | 44* | 62* | 79* |
| Cancer | ||||||||
| Yes | 2.8 | 10,444 | − 1137* | − 1022* | − 905* | − 789* | − 673* | − 557* |
| No | 93.0 | 2260 | 23* | 20* | 17 | 14 | 10 | 7 |
| Missing | 4.2 | 2969 | − 45* | − 28* | − 11 | 6 | 23* | 40* |
| Migraine | ||||||||
| Yes | 12.4 | 2286 | − 107* | − 98* | − 89* | − 81* | − 72* | − 63* |
| No | 74.5 | 2341 | 30* | 24* | 17 | 11 | 5 | − 1 |
| Missing | 13.1 | 3193 | − 48* | − 23 | 2 | 28* | 53* | 79* |
| Blood pressure | ||||||||
| Yes | 22.0 | 4415 | − 208* | − 150* | − 91* | − 32* | 27 | 86* |
| No | 65.4 | 1897 | 49* | 32* | 15 | − 2 | − 19* | − 35* |
| Missing | 12.7 | 3035 | − 17 | 4 | 26* | 48* | 69* | 91* |
| Blood vessels | ||||||||
| Yes | 3.6 | 7507 | − 552* | − 421* | − 291* | − 160* | − 29 | 102* |
| No | 83.6 | 2198 | 20* | 13 | 5 | − 2 | − 9 | − 16 |
| Missing | 12.7 | 3081 | − 28* | − 5 | 18 | 41* | 64* | 88* |
| Asthma | ||||||||
| Yes | 8.6 | 4702 | − 263* | − 182* | − 100* | − 19 | 63* | 144* |
| No | 78.9 | 2127 | 28* | 16 | 5 | − 6 | − 18 | − 29* |
| Missing | 12.5 | 3035 | − 16 | 6 | 28* | 51* | 73* | 95* |
| Psoriasis | ||||||||
| Yes | 2.9 | 3743 | − 383* | − 349* | − 314* | − 280* | − 245* | − 211* |
| No | 83.8 | 2290 | 13 | 7 | 2 | − 3 | − 8 | − 13 |
| Missing | 13.3 | 3156 | − 5 | 21 | 48* | 74* | 101* | 127* |
| Eczema | ||||||||
| Yes | 4.2 | 2758 | − 150* | − 136* | − 122* | − 108* | − 94* | − 80* |
| No | 83.0 | 2316 | 15 | 10 | 6 | 1 | − 3 | − 8 |
| Missing | 12.8 | 3142 | − 44* | − 20 | 5 | 30* | 54* | 79* |
| Severe/recurring dizziness | ||||||||
| Yes | 4.3 | 5772 | − 502* | − 400* | − 299* | − 197* | − 95* | 7 |
| No | 82.9 | 2180 | 28* | 19* | 11 | 2 | − 6 | − 15 |
| Missing | 12.8 | 3095 | − 27* | − 3 | 21 | 45* | 68* | 92* |
| Severe/recurring disease of intestines | ||||||||
| Yes | 4.4 | 5273 | − 590* | − 514* | − 438* | − 362* | − 285* | − 209* |
| No | 83.1 | 2202 | 34* | 26* | 19 | 12 | 4 | − 3 |
| Missing | 12.4 | 3076 | − 26* | − 3 | 20 | 43* | 66* | 90* |
| Incontinence | ||||||||
| Yes | 8.2 | 5579 | − 240* | − 154* | − 67* | 19 | 105* | 191* |
| No | 79.0 | 2099 | 24* | 13 | 3 | − 7 | − 17 | − 28* |
| Missing | 12.8 | 3085 | − 36* | − 13 | 10 | 34* | 57* | 80* |
| Wear of joint | ||||||||
| Yes | 18.6 | 4858 | − 267* | − 191* | − 115* | − 39* | 37* | 113* |
| No | 69.2 | 1929 | 48* | 31* | 14 | − 2 | − 19* | − 36* |
| Missing | 12.2 | 2982 | − 10 | 11 | 32* | 53* | 74* | 95* |
| Joint inflammation | ||||||||
| Yes | 6.4 | 5804 | − 354* | − 241* | − 127* | − 14 | 100* | 214* |
| No | 80.8 | 2143 | 24* | 13 | 3 | − 8 | − 18 | − 28* |
| Missing | 12.8 | 3076 | − 18 | 5 | 29* | 52* | 76* | 100* |
| Severe/recurring condition of back | ||||||||
| Yes | 11.0 | 3987 | − 233* | − 174* | − 115* | − 55* | 4 | 64* |
| No | 76.5 | 2151 | 33* | 21* | 10 | − 1 | − 12 | − 23* |
| Missing | 12.5 | 3023 | − 20 | 2 | 25* | 47* | 69* | 92* |
| Severe/recurring condition of neck | ||||||||
| Yes | 10.1 | 3706 | − 171* | − 117* | − 63* | − 9 | 45* | 100* |
| No | 77.3 | 2191 | 25* | 15 | 5 | − 5 | − 15 | − 25* |
| Missing | 12.5 | 3064 | − 32* | − 10 | 12 | 34* | 56* | 78* |
| Severe/recurring condition of elbow | ||||||||
| Yes | 6.9 | 4378 | − 184* | − 112* | − 39* | 33* | 106* | 179* |
| No | 80.4 | 2193 | 20* | 10 | 1 | − 8 | − 17 | − 26* |
| Missing | 12.7 | 3100 | − 39* | − 17 | 7 | 30* | 53* | 76* |
| Other | ||||||||
| Yes | 15.0 | 4860 | − 375* | − 311* | − 247* | − 183* | − 118* | − 54* |
| No | 74.6 | 1900 | 74* | 58* | 43* | 27* | 12 | − 3 |
| Missing | 10.4 | 3092 | − 34* | − 10 | 14 | 38* | 62* | 86* |
*Statistically significantly different from zero (P < 0.05)